Clarifying the conundrum of conjunctive anticoagulation and coronary thrombolysis.
Sobel
B E
BE
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006629:Hirudins / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D015912:Thrombolytic Therapy / Q000009:adverse effects
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006629:Hirudins; D006493:Heparin